CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$7.06M |
| 3 |
NVIDIA
NVDA
|
$6.46M |
| 4 |
Microsoft
MSFT
|
$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
$5.72M |
| 2 |
GSK
GSK
|
$5.14M |
| 3 |
Pinduoduo
PDD
|
$3.46M |
| 4 |
Procter & Gamble
PG
|
$2.91M |
| 5 |
Synopsys
SNPS
|
$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
MaxCyte
MXCT
$150M
| $93K | 0.01% |
22,366
+2,154
| +11% | +$8.96K |
|
402
iShares Russell Top 200 Growth ETF
IWY
$15B
| $92K | 0.01% |
+391
| New | +$92K |
|
403
Esperion Therapeutics
ESPR
$506M
| $91.9K | 0.01% |
+41,779
| New | +$91.9K |
|
404
SIGA Technologies
SIGA
$620M
| $91K | 0.01% |
15,140
+1,413
| +10% | +$8.49K |
|
405
OmniAb
OABI
$229M
| $90.8K | 0.01% |
25,659
+2,932
| +13% | +$10.4K |
|
406
Phibro Animal Health
PAHC
$1.6B
| $90.6K | 0.01% |
4,312
+400
| +10% | +$8.4K |
|
407
Monte Rosa Therapeutics
GLUE
$296M
| $90.4K | 0.01% |
+13,027
| New | +$90.4K |
|
408
KalVista Pharmaceuticals
KALV
$803M
| $87.5K | 0.01% |
10,329
+2,043
| +25% | +$17.3K |
|
409
Aura Biosciences
AURA
$402M
| $87.1K | 0.01% |
+10,592
| New | +$87.1K |
|
410
Personalis
PSNL
$472M
| $86.6K | 0.01% |
+14,980
| New | +$86.6K |
|
411
AnaptysBio
ANAB
$621M
| $85.4K | 0.01% |
6,452
+644
| +11% | +$8.53K |
|
412
abrdn Physical Silver Shares ETF
SIVR
$2.55B
| $82.7K | 0.01% |
3,000
-71,900
| -96% | -$1.98M |
|
413
Codexis
CDXS
$221M
| $82.3K | 0.01% |
+17,255
| New | +$82.3K |
|
414
Galapagos
GLPG
$2.21B
| $81.5K | 0.01% |
2,962
-937
| -24% | -$25.8K |
|
415
Prime Medicine
PRME
$693M
| $81.2K | 0.01% |
27,811
+4,725
| +20% | +$13.8K |
|
416
Regenxbio
RGNX
$479M
| $81.2K | 0.01% |
10,505
+999
| +11% | +$7.72K |
|
|
ALMS
417
Alumis Inc. Common Stock
ALMS
$450M
| $78.7K | 0.01% |
+10,013
| New | +$78.7K |
|
418
Sana Biotechnology
SANA
$762M
| $77.2K | 0.01% |
47,341
+4,554
| +11% | +$7.42K |
|
419
Taysha Gene Therapies
TSHA
$884M
| $75.2K | 0.01% |
43,456
+4,039
| +10% | +$6.99K |
|
420
Y-mAbs Therapeutics
YMAB
$390M
| $74.4K | 0.01% |
9,497
+925
| +11% | +$7.24K |
|
421
Design Therapeutics
DSGN
$331M
| $74.1K | 0.01% |
+12,006
| New | +$74.1K |
|
422
Corvus Pharmaceuticals
CRVS
$440M
| $72.9K | 0.01% |
+13,625
| New | +$72.9K |
|
423
Neurogene
NGNE
$278M
| $72K | 0.01% |
+3,150
| New | +$72K |
|
424
Olema Pharmaceuticals
OLMA
$520M
| $70.8K | 0.01% |
12,149
+1,135
| +10% | +$6.62K |
|
|
SAGE
425
DELISTED
Sage Therapeutics
SAGE
| $70.4K | 0.01% |
12,971
+1,229
| +10% | +$6.67K |
|